RLAY

Relay Therapeutics, Inc.

9.38 USD
+0.01 (+0.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Relay Therapeutics, Inc. stock is up 23.91% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November.

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial.